Camptothecin Analogs for Cancer Therapy
Camptothecin Analogs for Cancer Therapy
批准号:
7326586
负责人:
Lee ROY MORGAN
金额:
$15.89万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-09-27 至 2008-09-26
关键词:
AminocamptothecinBiological AssayCamptothecinCamptothecin AnalogueCharacteristicsChildhoodDevelopmentDipeptidesDrug KineticsHypoxiaIn VitroInstitutesLactonesMalignant NeoplasmsMitochondrial Carnitine Palmitoyltransferase PathwayModelingNeuroblastomaPhasePhase I Clinical TrialsProdrugsProtocols documentationResearchResearch InstituteScreening procedureTissuesUniversitiesVascular blood supplyWaterXenograft procedureanalogcancer therapydesignin vivonovelpre-clinicalpreclinical studytumor
中文摘要
描述(由申请人提供):7-丁基-10-氨基喜树碱(BACPT)及其水溶性二肽前药是一种新型喜树碱,被设计用于治疗儿童神经母细胞瘤。这些CPT类似物是内酯,在酸性缺氧组织中活性增加,这是快速生长的癌症的特征,其特征是血液供应增加。初步的体外和体内研究提出,以支持记录其他肿瘤模型可能更敏感。第一阶段研究的具体目标是:1。合成7-丁基-10-氨基amptothecin (BACPT)及其水溶性二肽前药BACPTDP, 100g量-足以用于临床前研究。2. 验证异种移植研究中的抗癌概况。3. 开发所需的分析分析,以记录纯度和稳定性,并开发/验证药代动力学研究的方案。完成这些研究后,将提交II期申请,以完成IND提交所需的临床前研究。BACPT和BACPTDP是杜克大学最初设计用于治疗儿童神经母细胞瘤的新型喜树碱。随后,DEKK-TEC与杜克大学和三角研究所(RTI)合作,完成了临床前开发,准备了IND,并为1期临床试验做好了准备。在后者之前,DEKK-TEC建议在广泛的肿瘤模型中筛选类似物,以确保产品的最佳癌症应用。
英文摘要
DESCRIPTION (provided by applicant): 7-butyl-10-aminocamptothecin (BACPT) and its water-soluble dipeptide pro-drug, are novel camptothecins that were designed to be used in the treatment of childhood neuroblastoma. These CPT analogs are lactones that have increased activity in acidic hypoxia tissues, characteristic of fast growing cancers that characteristically out grow their blood supply. Preliminary in vitro and in vivo studies are presented to support documenting other tumor models that might be more sensitive. The specific objectives of this Phase I study will be to: 1. Synthesize 7-butyl-10-aminocamptothecin (BACPT) and its water-soluble dipeptide pro-drug, BACPTDP in 100 g quantities - sufficient for preclinical studies. 2. Verify the anticancer profile in xenograft studies. 3. Develop the analytical assays required to document purity and stability and develop/validate protocols for pharmacokinetic studies. Upon completion of these studies a Phase II application will be submitted for completion of preclinical studies required for IND submission. BACPT and BACPTDP are novel camptothecins that were originally designed at Duke University to be used in the treatment of childhood neuroblastoma. Subsequently, DEKK-TEC has partnered with Duke and Research Triangle Institute (RTI) to complete the pre-clinical development, prepare the IND and ready the products for a Phase 1 clinical trial. Prior to the latter, DEKK-TEC proposes screening the analogs in a wide spectrum of tumor models to insure the best cancer applications for the products.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.tips.2012.02.001
发表时间:
2012-04
期刊:
Trends in pharmacological sciences
影响因子:
13.8
作者:
[Adams DJ]
通讯作者:
Adams DJ
DOI:
10.1007/s00280-010-1388-8
发表时间:
2011-04
期刊:
CANCER CHEMOTHERAPY AND PHARMACOLOGY
影响因子:
3
作者:
[Adams, David J., Waud, William R., Wani, Mansukh C., Manikumar, Govindarajan, Flowers, James L., Driscoll, Timothy A., Morgan, Lee Roy]
通讯作者:
Morgan, Lee Roy
A Phase I Clinical Trial: Binary Therapy with DM-CHOC-PEN and WBRT in Adults with Cancer Involving the CNS
-
批准号:9253561
-
项目类别:
-
资助金额:$14.33万
-
财政年份:2017
-
负责人:Lee ROY MORGAN
-
依托单位:
Phase I Clinical trial with 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Children with Cancer Involving the CNS
-
批准号:9047161
-
项目类别:
-
资助金额:$9.04万
-
财政年份:2016
-
负责人:Lee ROY MORGAN
-
依托单位:
Phase I Clinical trial with 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Children with Cancer Involving the CNS
-
批准号:9201324
-
项目类别:
-
资助金额:$9.04万
-
财政年份:2016
-
负责人:Lee ROY MORGAN
-
依托单位:
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN: A Phase II Clinical Trial in Adolescents/Young Adults (AYA)with CNS Malignancies
-
批准号:9791343
-
项目类别:
-
资助金额:$51.95万
-
财政年份:2016
-
负责人:Lee ROY MORGAN
-
依托单位:
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN): A Phase II Clinica
-
批准号:8685151
-
项目类别:
-
资助金额:$52.29万
-
财政年份:2008
-
负责人:Lee ROY MORGAN
-
依托单位:
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) Phase I Clinical Tr
-
批准号:7661596
-
项目类别:
-
资助金额:$13.17万
-
财政年份:2008
-
负责人:Lee ROY MORGAN
-
依托单位:
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN): A Phase II Clinica
-
批准号:8523101
-
项目类别:
-
资助金额:$63.86万
-
财政年份:2008
-
负责人:Lee ROY MORGAN
-
依托单位:
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) Phase I Clinical Tr
-
批准号:7481597
-
项目类别:
-
资助金额:$14.1万
-
财政年份:2008
-
负责人:Lee ROY MORGAN
-
依托单位:
Camptothecin Analogs for Cancer Therapy
-
批准号:7909166
-
项目类别:
-
资助金额:$44.49万
-
财政年份:2007
-
负责人:Lee ROY MORGAN
-
依托单位:
Camptothecin Analogs for Cancer Therapy
-
批准号:8136601
-
项目类别:
-
资助金额:$39.23万
-
财政年份:2007
-
负责人:Lee ROY MORGAN
-
依托单位:
A-007: Immune Modulation of HPV - Associated Neoplasia
-
批准号:6934739
-
项目类别:
-
资助金额:$80.55万
-
财政年份:2005
-
负责人:Lee ROY MORGAN
-
依托单位:
Clinical Development of 4-Hydroperoxyifosfamide
-
批准号:6549338
-
项目类别:
-
资助金额:$18.56万
-
财政年份:2002
-
负责人:Lee ROY MORGAN
-
依托单位:
Clinical Development of 4-Hydroperoxyifosfamide
-
批准号:7227505
-
项目类别:
-
资助金额:$24.49万
-
财政年份:2002
-
负责人:Lee ROY MORGAN
-
依托单位:
Clinical Development of 4-Hydroperoxyifosfamide
-
批准号:7109630
-
项目类别:
-
资助金额:$29.43万
-
财政年份:2002
-
负责人:Lee ROY MORGAN
-
依托单位:
A-007: IMMUNE MODULATION OF HPV - CERVICAL CANCER
-
批准号:6287882
-
项目类别:
-
资助金额:$19.15万
-
财政年份:2001
-
负责人:Lee ROY MORGAN
-
依托单位:
DERIVATIVES OF DEMETHYLPENCLOMEDINE:ANTICANCER AGENTS
-
批准号:6074558
-
项目类别:
-
资助金额:$12.7万
-
财政年份:2000
-
负责人:Lee ROY MORGAN
-
依托单位:
DERIVATIVES OF DEMETHYLPENCLOMEDINE:ANTICANCER AGENTS
-
批准号:6633616
-
项目类别:
-
资助金额:$32.04万
-
财政年份:2000
-
负责人:Lee ROY MORGAN
-
依托单位:
DERIVATIVES OF DEMETHYLPENCLOMEDINE:ANTICANCER AGENTS
-
批准号:6344477
-
项目类别:
-
资助金额:$35.95万
-
财政年份:2000
-
负责人:Lee ROY MORGAN
-
依托单位:
DERIVATIVES OF DEMETHYLPENCLOMEDINE:ANTICANCER AGENTS
-
批准号:6514358
-
项目类别:
-
资助金额:$12.26万
-
财政年份:2000
-
负责人:Lee ROY MORGAN
-
依托单位:
ISOPHOSPHORAMIDE MUSTARD--A PHASE 1 STUDY
-
批准号:6211058
-
项目类别:
-
资助金额:$22.59万
-
财政年份:1999
-
负责人:Lee ROY MORGAN
-
依托单位:
海外基金